MA33134B1 - Derives d'indole en tant qu'antagonistes du recepteur crth2 - Google Patents

Derives d'indole en tant qu'antagonistes du recepteur crth2

Info

Publication number
MA33134B1
MA33134B1 MA34181A MA34181A MA33134B1 MA 33134 B1 MA33134 B1 MA 33134B1 MA 34181 A MA34181 A MA 34181A MA 34181 A MA34181 A MA 34181A MA 33134 B1 MA33134 B1 MA 33134B1
Authority
MA
Morocco
Prior art keywords
receptor antagonists
indole derivatives
crth2 receptor
crth2
pgd2
Prior art date
Application number
MA34181A
Other languages
English (en)
Inventor
Carl Berthelette
Michael Boyd
John Colucci
Karine Villeneuve
Joey Methot
Original Assignee
Merck Canada Inc
Merck Sharp & Dohme
Abu Ghazaleh Intellectual Prop
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Canada Inc, Merck Sharp & Dohme, Abu Ghazaleh Intellectual Prop filed Critical Merck Canada Inc
Publication of MA33134B1 publication Critical patent/MA33134B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur des composés de formule (I) qui sont des antagonistes du récepteur PGD2, CRTH2, et qui, en tant que tels, sont utiles dans le traitement et/ou la prévention de maladies à médiation par CRTH2 telles que l'asthme.
MA34181A 2009-02-24 2010-02-19 Derives d'indole en tant qu'antagonistes du recepteur crth2 MA33134B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15496809P 2009-02-24 2009-02-24
PCT/US2010/024713 WO2010099039A1 (fr) 2009-02-24 2010-02-19 Dérivés d'indole en tant qu'antagonistes du récepteur crth2

Publications (1)

Publication Number Publication Date
MA33134B1 true MA33134B1 (fr) 2012-03-01

Family

ID=42046150

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34181A MA33134B1 (fr) 2009-02-24 2010-02-19 Derives d'indole en tant qu'antagonistes du recepteur crth2

Country Status (36)

Country Link
US (2) US8394819B2 (fr)
EP (2) EP2492267B1 (fr)
JP (1) JP4989786B1 (fr)
KR (2) KR101275980B1 (fr)
CN (1) CN102333771B (fr)
AR (1) AR075597A1 (fr)
AU (1) AU2010218209B2 (fr)
BR (1) BRPI1008906B1 (fr)
CA (1) CA2752981C (fr)
CL (1) CL2011002056A1 (fr)
CO (1) CO6410295A2 (fr)
CR (1) CR20110455A (fr)
DK (1) DK2401269T3 (fr)
DO (1) DOP2011000271A (fr)
EA (1) EA021076B1 (fr)
EC (1) ECSP11011288A (fr)
ES (2) ES2529420T3 (fr)
HN (1) HN2011002272A (fr)
HR (1) HRP20140384T1 (fr)
IL (1) IL214342A0 (fr)
MA (1) MA33134B1 (fr)
MX (1) MX2011008869A (fr)
MY (1) MY152062A (fr)
NI (1) NI201100162A (fr)
NZ (1) NZ594767A (fr)
PE (1) PE20120056A1 (fr)
PL (1) PL2401269T3 (fr)
PT (1) PT2401269E (fr)
RS (1) RS53268B (fr)
SG (1) SG173775A1 (fr)
SI (1) SI2401269T1 (fr)
TN (1) TN2011000382A1 (fr)
TW (2) TWI444381B (fr)
UA (1) UA105039C2 (fr)
WO (1) WO2010099039A1 (fr)
ZA (1) ZA201105767B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637671B2 (en) * 2008-09-22 2014-01-28 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
US8546422B2 (en) * 2008-09-22 2013-10-01 Merck Canada Inc. Azaindole derivatives as CRTH2 receptor antagonists
WO2012087872A1 (fr) 2010-12-23 2012-06-28 Merck Sharp & Dohme Corp. Quinoléines et aza-quinoléines en tant que modulateurs de l'activité du récepteur crth2
ES2635030T3 (es) 2010-12-23 2017-10-02 Merck Sharp & Dohme Corp. Quinoxalinas y aza-quinoxalinas como moduladores del receptor CRTH2
MY165623A (en) * 2011-04-14 2018-04-18 Idorsia Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2012174176A1 (fr) * 2011-06-17 2012-12-20 Merck Sharp & Dohme Corp. Tétrahydroquinolines à fusion cycloalkyle en tant que modulateurs de l'activité du récepteur crth2
US20130072470A1 (en) 2011-09-21 2013-03-21 Abbvie Inc. Novel tricyclic compounds
CN103450218B (zh) * 2012-05-29 2015-12-23 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的吲哚类三并环衍生物
US9290454B2 (en) 2012-10-01 2016-03-22 Merck Sharp & Dohme Corp. Substituted isoquinolines as CRTH2 receptor modulators
WO2014060596A1 (fr) * 2012-10-18 2014-04-24 Zach System S.P.A. Procédé de préparation de dérivés d'indole
HRP20181555T1 (hr) 2014-03-17 2018-11-30 Idorsia Pharmaceuticals Ltd Derivati azaindol-octene kiseline i njihova uporaba kao modulatora receptora prostaglandina d2
RU2016140708A (ru) 2014-03-18 2018-04-18 Идорсиа Фармасьютиклз Лтд Производные азаиндол уксусной кислоты и их применение в качестве модуляторов рецептора простагландина d2
PT3277722T (pt) 2015-04-02 2021-10-06 Intervet Int Bv Anticorpos para recetor alfa da interleucina-4 canina
WO2017005764A1 (fr) * 2015-07-07 2017-01-12 Intervet International B.V. Procédé de production d'intermédiaires tricyclocétones d'antagonistes de crth2
WO2017005766A1 (fr) 2015-07-07 2017-01-12 Intervet International B.V. Procédé de production d'intermédiaires alcools tricycliques d'antagonistes de crth2
WO2017005759A1 (fr) 2015-07-07 2017-01-12 Intervet International B.V. Procédé pour produire des dérivés d'azaindole
MX2018000947A (es) 2015-07-23 2018-06-07 Merck Sharp & Dohme Marcadores geneticos asociados con la respuesta a los antagonistas del receptor crth2.
PL3350179T3 (pl) 2015-09-15 2021-08-02 Idorsia Pharmaceuticals Ltd Krystaliczne postacie
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
KR20250010141A (ko) 2015-10-16 2025-01-20 애브비 인코포레이티드 (3S,4R)-3-에틸-4-(3H-이미다조[1,2-a]피롤로[2,3-e]-피라진-8-일)-N-(2,2,2-트리플루오로에틸)피롤리딘-1-카복스아미드및 이의 고체상 형태의 제조 방법
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
RU2761249C2 (ru) 2016-12-14 2021-12-06 Мерк Шарп энд Доум Корп. Человеческие генетические маркеры, ассоциированные с ответом на средства для лечения, которые целенаправленно воздействуют на токсин b clostridium difficile
CN114829396A (zh) 2019-12-20 2022-07-29 英特维特国际股份有限公司 用于治疗特应性皮炎的双特异性犬源化抗体和双特异性结合伴体
EP4388006A1 (fr) 2021-08-20 2024-06-26 Intervet International B.V. Protéines de fusion homodimères pour le traitement de la dermatite atopique

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
EP0769958B1 (fr) 1994-07-11 2003-04-16 Athena Neurosciences, Inc. Inhibiteurs de l'adhesion leucocytaire
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
WO1996031206A2 (fr) 1995-04-07 1996-10-10 Warner-Lambert Company Flavones et coumarines utilisees en tant qu'agents dans le traitement de l'atherosclerose
WO1996040781A1 (fr) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. INHIBITEURS PEPTIDIQUES CYCLIQUES D'ADHERENCE CELLULAIRE INDUITE PAR INTEGRINE β1 ET β¿2?
AU6311996A (en) 1995-07-06 1997-02-05 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
FR2827206B1 (fr) 2001-07-10 2004-04-02 Nature Bois Emballages Procede et dispositif de formage de planchettes, et emballages comportant de telles planchettes
JP4484108B2 (ja) 2002-05-16 2010-06-16 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗作用を有する化合物
WO2004103970A1 (fr) * 2003-05-20 2004-12-02 Merck Frosst Canada Ltd. Fluoro-methanesulfonyl- cycloalkanoindoles substitues et leur utilisation en tant qu'antagonistes de prostaglandine d2
RU2387652C2 (ru) * 2004-03-11 2010-04-27 Актелион Фармасьютиклз Лтд Производные тетрагидропиридоиндола
WO2006015191A2 (fr) 2004-07-29 2006-02-09 Threshold Pharmaceuticals, Inc. Analogues de lonidamine multicycliques
GB0427381D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
PL1833791T3 (pl) * 2004-12-27 2011-12-30 Actelion Pharmaceuticals Ltd Pochodne 2,3,4,9-tetrahydro-1H-karbazolu jako antagonisty receptora CRTH2
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
US7696222B2 (en) 2005-08-12 2010-04-13 Merck Frosst Canada Ltd Indole derivatives as CRTH2 receptor antagonists
KR101411820B1 (ko) * 2006-08-07 2014-06-24 액테리온 파마슈티칼 리미티드 (3-아미노-1,2,3,4-테트라하이드로-9ｈ-카르바졸-9-일)-아세트산 유도체
US20110112134A1 (en) 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
US8546422B2 (en) 2008-09-22 2013-10-01 Merck Canada Inc. Azaindole derivatives as CRTH2 receptor antagonists
US8637671B2 (en) 2008-09-22 2014-01-28 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
US8637541B2 (en) 2008-09-22 2014-01-28 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
WO2010085820A2 (fr) 2009-01-26 2010-07-29 Amira Pharmaceuticals, Inc. Composés tricycliques en tant qu'antagonistes des récepteurs d2 de la prostaglandine

Also Published As

Publication number Publication date
TW201402573A (zh) 2014-01-16
BRPI1008906A2 (pt) 2016-03-15
EP2492267B1 (fr) 2014-11-26
NI201100162A (es) 2012-02-01
JP2012517484A (ja) 2012-08-02
ECSP11011288A (es) 2011-10-31
TN2011000382A1 (en) 2013-03-27
AR075597A1 (es) 2011-04-20
EP2492267A1 (fr) 2012-08-29
US9023864B2 (en) 2015-05-05
PL2401269T3 (pl) 2014-07-31
PT2401269E (pt) 2014-03-11
HRP20140384T1 (en) 2014-05-23
CL2011002056A1 (es) 2012-04-09
CA2752981A1 (fr) 2010-09-02
US8394819B2 (en) 2013-03-12
NZ594767A (en) 2013-05-31
ES2450594T3 (es) 2014-03-25
CN102333771B (zh) 2014-03-19
HN2011002272A (es) 2014-02-24
EA021076B1 (ru) 2015-03-31
TWI454474B (zh) 2014-10-01
US20130150398A1 (en) 2013-06-13
ES2529420T3 (es) 2015-02-19
SG173775A1 (en) 2011-09-29
PE20120056A1 (es) 2012-02-05
KR101276530B1 (ko) 2013-06-18
EA201171081A1 (ru) 2012-02-28
HK1160465A1 (en) 2012-08-17
CO6410295A2 (es) 2012-03-30
CR20110455A (es) 2012-01-10
WO2010099039A1 (fr) 2010-09-02
KR101275980B1 (ko) 2013-06-17
BRPI1008906B1 (pt) 2019-10-15
US20100234415A1 (en) 2010-09-16
TW201035096A (en) 2010-10-01
MX2011008869A (es) 2011-12-16
RS53268B (sr) 2014-08-29
IL214342A0 (en) 2011-09-27
MY152062A (en) 2014-08-15
EP2401269A1 (fr) 2012-01-04
KR20110107395A (ko) 2011-09-30
DOP2011000271A (es) 2011-10-15
DK2401269T3 (da) 2014-04-28
CN102333771A (zh) 2012-01-25
SI2401269T1 (sl) 2014-04-30
JP4989786B1 (ja) 2012-08-01
UA105039C2 (uk) 2014-04-10
AU2010218209B2 (en) 2012-12-13
CA2752981C (fr) 2013-11-12
TWI444381B (zh) 2014-07-11
EP2401269B1 (fr) 2014-01-29
AU2010218209A1 (en) 2011-08-25
KR20130028156A (ko) 2013-03-18
ZA201105767B (en) 2012-04-25

Similar Documents

Publication Publication Date Title
MA33134B1 (fr) Derives d'indole en tant qu'antagonistes du recepteur crth2
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA32131B1 (fr) Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
MA31767B1 (fr) Composes organiques et leurs utilisations
TN2011000454A1 (fr) Derives de benzofurannyle utilises comme inhibiteurs de glucokinase
MA29568B1 (fr) Composes d'azaindazole et methodes d'utilisation desdits composes
MA31457B1 (fr) N-(2-(hetaryl)aryl)arylsulfonamides et n-(2-(hetaryl)hetaryl)arylsulfonamides
EP1993560A4 (fr) Antagonistes de recepteur cannabinoide/agonistes inverses utiles dans le traitement de l'obesite
MA42145B1 (fr) Triazoles agonistes du récepteur apj
MA33334B1 (fr) Derives de l-(piperidine-4-yl)-pyrazole servant de modulateurs de gpr 119
ATE556060T1 (de) Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
MA30324B1 (fr) Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine.
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
ATE464304T1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonist n
ATE469895T1 (de) Cgrp-rezeptorantagonisten
NZ548954A (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
GT200600093A (es) Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias
MA32627B1 (fr) Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase
MA29723B1 (fr) Composes
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases